FANCC

Across TCGA pan-cancer cohorts, FANCC Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FANCC data layer compared with 24 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FANCC Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FANCC expression acts as an unfavorable survival marker.

LIHC, LUSC, and ESCA are the cancer types where FANCC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.072	0.555	<.001	18	view →
LUSC	DFS	Median	All	0.463	0.761	.015	12	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FANCC–LIHC (DFS)

Open the LIHC breakdown →